---
title: "Medicus Pharma Streamlines Phase 2 Teverelix Trial for $2 Billion AUR Market"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281766832.md"
description: "Medicus Pharma Streamlines Phase 2 Teverelix Trial for $2 Billion AUR Market"
datetime: "2026-04-06T13:42:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281766832.md)
  - [en](https://longbridge.com/en/news/281766832.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281766832.md)
generator: "portal-rs"
---

# Medicus Pharma Streamlines Phase 2 Teverelix Trial for $2 Billion AUR Market

Medicus Pharma Streamlines Phase 2 Teverelix Trial for $2 Billion AUR Market

### Related Stocks

- [MDCX.US](https://longbridge.com/en/quote/MDCX.US.md)
- [MDCXW.US](https://longbridge.com/en/quote/MDCXW.US.md)

## Related News & Research

- [Medicus Pharma signs co-development, licensing deal with Pfizer for CD228V antibody-drug conjugate](https://longbridge.com/en/news/297910433.md)
- [Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update | MDCX Stock News](https://longbridge.com/en/news/295715209.md)
- [Innocan Pharma reports Q2 results](https://longbridge.com/en/news/297557245.md)
- [Braidwell LP Invests $26.38 Million in Avalyn Pharma Inc. $AVLN](https://longbridge.com/en/news/297882653.md)
- [Vidac Pharma board member Dr. Max Herzberg sells shares for EUR 5,375](https://longbridge.com/en/news/297966632.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**